Optimal management of platelet function after coronary stenting

Current Treatment Options in Cardiovascular Medicine

Volumn 9, Issue 1, 2007, Pages 37-45

  Park, Seung Jung ^a   Lee, Seng Whan ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ABCIXIMAB; ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CANGRELOR; CAPTOPRIL; CILOSTAZOL; CLOPIDOGREL; DILTIAZEM; DIPYRIDAMOLE; EPTIFIBATIDE; ERYTHROMYCIN; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; HEPARIN; IBUPROFEN; KETOCONAZOLE; NAPROXEN; OMEPRAZOLE; PHENYTOIN; PLACEBO; PRASUGREL; TAMOXIFEN; TAMOXIFEN CITRATE; TICLOPIDINE; TIROFIBAN; TOLBUTAMIDE; TORASEMIDE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; APLASTIC ANEMIA; ARTERY INJURY; ARTHRALGIA; ASTHENIA; BACKACHE; BLEEDING; BRAIN HEMORRHAGE; BRONCHITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY STENT; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ELUTING STENT; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; FLUID RETENTION; HEART DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART TAMPONADE; HEARTBURN; HEMATURIA; HEMOPTYSIS; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERESTHESIA; HYPERTENSION; INDIGESTION; LEG CRAMP; LOADING DRUG DOSE; META ANALYSIS; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OCCULT BLOOD; PAIN; PARESTHESIA; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE THROMBOSIS; PRURITUS; REVIEW; SIDE EFFECT; SKIN BRUISING; SKIN DISCOLORATION; STOMACH DISEASE; STOMACH HEMORRHAGE; STOMACH PAIN; STOMACH ULCER; SURGICAL MORTALITY; SWELLING; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

EID: 34147198300     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-007-0049-7     Document Type: Review

References (53)

1. Gawaz M, Neumann FJ, Ott I, et al.: Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart 1996, 76:166-172.
2. Inoue T, Sohma R, Miyazaki T, et al.: Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol 2000, 86:1057-1062.
3. Leon MB, Baim DS, Popma JJ, et al.: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998, 339:1665-1671.
4. Cutlip DE, Baim DS, Ho KK, et al.: Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001, 103:1967-1971.
5. Karrillon GJ, Morice MC, Benveniste E, et al.: Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registry. Circulation 1996, 94:1519-1527.
6. Moussa I, Di Mario C, Reimers B, et al.: Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 1997, 29:6-12.
7. Iskovou I, Schmidt T, Bonizzoni et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126-2130.
8. Antithrombotic Trialists' Colloboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
9. Barnathan E, Schwartz J, Taylor L, et al.: Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987, 76:125-134.
10. Schwartz L, Bourassa M, Lesperance J, et al.: Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988, 318:1714-1719.
11. Lembo NJ, Black AJ, Roubin GS, et al.: Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990, 65:422-426.
12. Bertrand ME, Legrand V, Boland J, et al.: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998, 98:1597-1603.
13. Savcic M, Hauert J, Bachmann F, et al.: Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Sem Thromb Hemost 1999, 25:15-19.
14. Schomig A, Neumann FJ, Kastrati A, et al.: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996, 334:1084-1089.
15. Muller C, Buttner H, Petersen J, et al.: A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000, 101:590-593.
16. Moussa I, Oetgen M, Roubin G, et al.: Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999, 99:2364-2366.
17. Mehta SR, Yusuf S, Peters RJ, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
18. Steinhubl S, Berger P, Mann J, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.
19. Sabatine MS, Cannon CP, Gibson CM, et al.: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005, 294:1224-1232.
20. Patti G, Colonna G, Pasceri V, et al.: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005, 111:2099-2106.
21. Kandzari DE, Berger PB, Kastrati A, et al.: Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004, 44:2133-2136.
22. Gurbel PA, Bliden KP, Hayes KM, et al.: The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005, 45:1392-1396.
23. Gurbel PA, Bliden KP, Hiatt BL, et al.: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908-2913.
24. Gurbel PA, Bliden KP, Zaman KA, et al.: Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005, 111:1153-1159.
25. Gurbel PA, Cummings CC, Bell CR, et al.: Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003, 145:239-247.
26. Gurbel PA, Samara WM, Bliden KP: Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets 2004, 15:95-99.
27. Müller I, Seyfarth M, Rüdiger S, et al.: Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001, 85:92-93.
28. Park SW, Lee CW, Kim HS, et al.: Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 1999, 84:511-514.
29. Yoon Y, Shim WH, Lee DH, et al.: Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol 1999, 84:1375-1380.
30. Hashiguchi M, Ohno K, Nakazawa R, et al.: Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Cardiovasc Drugs Ther 2004, 18:211-217.
31. Lee SW, Park SW, Hong MK, et al.: Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol 2005, 95:859-862.
32. Ahn JC, Song WH, Kwon JA, et al.: Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel. Korean J Intern Med 2004, 19:230-236.
33. Lee SW, Park SW, Hong MK, et al.: Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005, 46:1833-1837.
34. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators [no authors listed]. N Engl J Med 1998, 339:436-443.
35. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non- Q-wave myocardial infarction. PRISM-PLUS Study Investigators [no authors listed]. N Engl J Med 1998, 338:1488-1497.
36. Bertrand ME, Simoons ML, Fox KA, et al.: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002, 23:1809-1840.
37. Theroux P, Alexander J Jr, Dupuis J, et al.: Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. Am J Cardiol 2001, 87:375-380.
38. Greenbaum AB, Harrington RA, Hudson MP, et al.: Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. J Am Coll Cardiol 2001, 37:492-498.
39. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting [no authors listed]. Lancet 1998, 352:87-92.
40. Bolognese L, Falsini G, Liistro F, et al.: Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006, 47:522-528.
41. Boden WE, McKay RG: Optimal treatment of acute coronary syndromes - an evolving strategy. N Engl J Med 2001, 344:1939-1942.
42. Boden WE: "Routine invasive" versus "selective invasive" approaches to non-ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era. J Am Coll Cardiol 2003, 41:113S-122S.
43. Gibson CM, Singh KP, Murphy SA, et al.: Braunwald E. Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy). Am J Cardiol 2004, 94:492-494.
44. Lange RA, Hillis LD: Antiplatelet therapy for ischemic heart disease. N Engl J Med 2004, 350:277-280.
45. Petronio AS, Musumeci G, Limbruno U, et al.: Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. Am Heart J 2002, 143:334-341.
46. Lev EI, Patel RT, Maresh KJ, et al.: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006, 47:27-33.
47. Sugidachi A, Asai F, Ogawa T, et al.: The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000, 129:1439-1446.
48. Niitsu Y, Jakubowski JA, Sugidachi A, et al.: Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005, 31:184-194.
49. Jernberg T, Payne CD, Winters KJ, et al.: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006, 27:1166-1173.
50. Storey RF, Oldroyd KG, Wilcox RG: Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001, 85:401-407.
51. Greenbaum AB, Grines CL, Bittl JA, et al.: Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006, 151:689.e1-689.e10.
52. van Giezen JJJ, Humphries RG: Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005, 31:195-204.
53. Husted S, Emanuelsson H, Heptinstall S, et al.: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006, 27:1038-1047.